Gene Variants in Components of the microRNA Processing Pathway in Chronic Myeloid Leukemia
- PMID: 39202414
- PMCID: PMC11353722
- DOI: 10.3390/genes15081054
Gene Variants in Components of the microRNA Processing Pathway in Chronic Myeloid Leukemia
Abstract
Current therapy in chronic myeloid leukemia (CML) has improved patient life expectancy close to that of healthy individuals. However, molecular alterations other than BCR::ABL1 fusion gene in CML are barely known. MicroRNAs are important regulators of gene expression, and variants in some of the components of microRNA biosynthesis pathways have been associated with genetic susceptibility to different types of cancer. Thus, the aim of this study was to evaluate the association of variants located in genes involved in the biogenesis of microRNAs with susceptibility to CML. Fifteen variants in eight genes involved in the biogenesis of miRNAs were genotyped in 296 individuals with CML and 485 healthy participants using TaqMan probes. The association of gene variants with CML and clinical variables was evaluated by a Chi-square test, and odds ratios and 95% confidence intervals were estimated by logistic regression. The variant rs13078 in DICER1 was significantly higher among CML individuals than in healthy participants. In addition, the variants rs7813 and rs2740349 were significantly associated with worse prognosis, according to their Hasford scores, whereas the rs2740349 variant was also associated with a later age at diagnosis. These findings suggest that variants in components of the microRNA biogenesis pathway could be involved in CML genetic risk.
Keywords: Hasford score; chronic myeloid leukemia; gene variants; microRNAs biogenesis.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
The rs61764370 Functional Variant in the KRAS Oncogene is Associated with Chronic Myeloid Leukemia Risk in Women.Asian Pac J Cancer Prev. 2016;17(4):2265-70. doi: 10.7314/apjcp.2016.17.4.2265. Asian Pac J Cancer Prev. 2016. PMID: 27221928
-
Single nucleotide polymorphism in PTEN-Long gene: A risk factor in chronic myeloid leukemia.Gene. 2019 Apr 30;694:71-75. doi: 10.1016/j.gene.2019.01.038. Epub 2019 Feb 7. Gene. 2019. PMID: 30738963
-
Polymorphisms in microRNA target sites modulate risk of lymphoblastic and myeloid leukemias and affect microRNA binding.J Hematol Oncol. 2014 Jun 2;7:43. doi: 10.1186/1756-8722-7-43. J Hematol Oncol. 2014. PMID: 24886876 Free PMC article.
-
Association between genetic variants in DICER1 and cancer risk: An updated meta-analysis.Gene. 2021 Jan 15;766:145132. doi: 10.1016/j.gene.2020.145132. Epub 2020 Sep 8. Gene. 2021. PMID: 32911029 Review.
-
The role of microRNAs in the development, progression and drug resistance of chronic myeloid leukemia and their potential clinical significance.Life Sci. 2022 May 1;296:120437. doi: 10.1016/j.lfs.2022.120437. Epub 2022 Feb 26. Life Sci. 2022. PMID: 35231484 Review.
Cited by
-
The biology of chronic myeloid leukemia: an overview of the new insights and biomarkers.Front Oncol. 2025 May 8;15:1546813. doi: 10.3389/fonc.2025.1546813. eCollection 2025. Front Oncol. 2025. PMID: 40406262 Free PMC article. Review.
References
-
- O’Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., Cornelissen J.J., Fischer T., Hochhaus A., Hughes T., et al. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. N. Engl. J. Med. 2003;348:994–1004. doi: 10.1056/NEJMoa022457. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous